Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Breast cancer is a leading cause of cancer death globally, with estrogen receptor-positive (ER+) subtypes prevalent.
• Selective estrogen receptor modulators (SERMs) are common treatments but face challenges like side effects and drug resistance in approximately 50% of patients.
• Existing SERMs can cause adverse effects due to off-target estrogenic activity in other tissues.

Purpose of the Study:

• To synthesize and evaluate novel 4,6-diaryl-2-pyrimidinamine derivatives as potential anti-breast cancer agents.
• To investigate compounds that simultaneously antagonize the estrogen receptor (ER) and inhibit vascular endothelial growth factor receptor 2 (VEGFR-2).
• To identify new therapeutic strategies for ER+ breast cancer, addressing limitations of current SERMs.

Main Methods:

• Synthesis of a series of 4,6-diaryl-2-pyrimidinamine derivatives.
• In vitro bioactivity evaluation, including inhibition of proliferation in MCF-7, HUVEC, and Ishikawa cells.
• In vivo studies to assess anti-angiogenic effects and estrogen action antagonism of lead compounds, such as compound III-3A.

Main Results:

• The synthesized compounds demonstrated significant inhibition of proliferation in tested cancer and endothelial cell lines.
• Compound III-3A effectively antagonized estrogen action and inhibited VEGFR-2 phosphorylation.
• Compound III-3A also exhibited anti-angiogenic activity in vivo, indicating a multi-targeted therapeutic potential.

Conclusions:

• The novel 4,6-diaryl-2-pyrimidinamine derivatives show significant potential as anti-breast cancer agents.
• Simultaneous ER antagonism and VEGFR-2 inhibition represent a promising dual-action strategy for ER+ breast cancer treatment.
• Further investigation of these compounds is warranted for their development into effective breast cancer therapeutics.